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Abstract 
Background: The most frequent intraocular malignant tumor is choroidal melanoma 
(CM). Although brain metastasis is a common feature of other types of cancers, 
metastasis of CM to the brain is a rare entity. 
Case Description: The authors report a case of a 28-year-old woman presenting 
with a single brain metastasis, 10 years after the treatment of a CM. She 
underwent a total en-bloc resection of the lesion, and the diagnosis was conﬁrmed 
histopathologically. The patient concomitantly received whole-brain irradiation 
therapy combined with chemotherapy, with a survival period of 24 months. 
Conclusion: The present case report draws attention to the necessity of a close 
and lifelong follow-up of patients treated for this malignancy. The international 
literature is also reviewed.
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INTRODUCTION
Choroidal melanoma (CM) is the most frequent intra-
ocular malignant tumor in adulthood.[11] Brain metastases 
are relatively rare, accounting for 2–5% of the overall 
incidence of metastases, and they are associated with a 
poor outcome, usually appearing concomitantly with 
liver metastases.[18] The authors describe a rare case of 
an isolated brain metastasis, appearing 10 years after 
treatment of the primary lesion that responded favorably 
to local resection combined with whole-brain irradiation 
therapy (WBRT) and chemotherapy. To the authors’ 
knowledge, there are only two similar articles in the 
English literature.[1,16] Patient’s family consent along 
with the institutional ethical committee’s permission for 
publication was granted.
CASE REPORT
A 28-year-old female patient was admitted to the 
Neurosurgery Unit of the Hospital da Restauração 
(Recife, PE, Brazil) with a recent history of intense 
headache that was not responsive to any kind of medical 
therapy. She complained of continuous headache almost 
every morning for the last 2 months. At the time of 
presentation, despite the mentioned symptoms, she was 
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neurologically intact. She showed neither any evidence 
of peripheral lymphadenopathy nor any pigmented 
lesions at the physical examination. Of note, she had 
a prosthetic eye on the right side. The medical history 
revealed that she had been operated on for a CM 10 
years ago. The surgical procedure involved enucleation of 
the right eye. The histopathologic study was consistent 
with a malignant CM. During the follow-up, no skeletal 
scintigraphy or magnetic resonance imaging (MRI) tests 
were performed.
All laboratory tests revealed nothing abnormal. Computed 
tomography (CT) and MRI scans were performed at day 
2 and a left frontal lobe lesion was illustrated. This lesion 
appeared hyperdense on CT scan [Figure 1], a finding 
that drew the attention to a possible recent intratumoral 
bleeding. However, it did not behave as blood on MRI 
study. It was hyperintense on T1-weighted images 
[Figure 2] and isointense on T2-weighted images. But 
when analyzing the gradient echo sequence (GRE), the 
lesion was isointense to the brain [Figure 3]. Since blood 
usually appears hypointense on GRE, the possibility of a 
late single brain metastatic melanoma became the most 
prominent diagnosis.
On the fourth day of hospitalization, the patient 
experienced worsening of the headache and became 
drowsy. New emergency CT scan showed increase of 
the midline shift, subfalcine and uncus herniation. The 
patient was taken to the operating room for a total 
resection of the tumor. The surgical procedure consisted 
of a left frontotemporal craniotomy and standard 
microsurgical techniques were employed to achieve an 
“en bloc” resection of the tumor. The histology of the 
lesion confirmed a metastatic melanoma of the brain 
[Figure 4]. Typical hyperchromatic and pleomorphic 
cells were recognized and special melanin stains [S100, 
Melan-A, homatropine methylbromide (HMB) 45] 
Figure 1: Hyperdense frontal lesion mimicking an intratumoral 
hemorrhage
Figure 2: T1-weighted images (contrast-enhanced) demonstrating 
a hyperintense left frontal lobe lesion
Figure 4: Histopathologic findings included dense deposit of melanin, 
intense tumoral necrosis and nuclear atypism with surrounding 
secondary lesions (H and E, ×300)
Figure 3: Gradient echo sequence: the lesion is isointense to the 
brain
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confirmed the diagnosis.
The patient received WBRT for 3 months with a total 
dose of 54 Gy combined with chemotherapy, consisting 
of increasing doses of temozolamide (Temodal®, Merck 
and Co., Inc., Whitehouse Station, NJ, USA) up to 150 
mg/m2/day. Thereafter, she had been closely followed up 
in the Ambulatory Department with no recurrence on 
serial MRI scans. She was asymptomatic for 24 months, 
when she was admitted to the hospital with shortness of 
breath and eventually died from pulmonary embolism. 
No autopsy was conducted due to her family’s religious 
beliefs.
DISCUSSION
CM is the most frequent intraocular malignant tumor in 
adulthood.[11] It has been estimated that the incidence of 
CM in the United States is six to seven cases per million 
per year.[18] Several risk factors for malignant CM have 
been identified. Women are slightly more affected than 
men and Whites have an eightfold increased risk than 
more darkly pigmented persons.[9] People with lightly 
colored irises have also increased risk to develop CM.[9,17] 
Prevalence increases with age as follows: 1 in 1 million 
before 30 years of age, 7 in 1 million before the age of 70 
years, and 50 in 1 million after 70 years of age.[6,9]
Multiple known and unknown factors may influence 
the prognosis of CM. Brain metastases from CM are 
relatively rare (2–5% of all brain metastases) and they are 
associated with poor prognosis, with life expectancy being 
less than 1 year. They are usually concomitant with liver 
metastases.[6,11,17] Liver metastases usually occur within 
the first 4 years after the treatment of the primary tumor. 
Other sites of disseminated disease are the lungs, bones, 
kidneys and brain.[1,3,11,16] Shields et al. reported on one 
case of a liver late metastasis from a CM, 42 years after 
the treatment of the primary tumor.[15]
In the early 90s, Lorigan et al. studied the clinical and 
radiological findings of 110 patients with metastatic CM, 
of which only 5 had brain metastases.[10] More recently, 
some studies have used positron emission tomography 
(PET) for staging the metastatic disease from CM. 
Using this method, Finger et al. evaluated a series of 52 
patients where the liver (100%), bone (50%) and lymph 
nodes (50%) were the main sites of metastases from 
CM. In this case series, only one patient had an isolated 
metastatic brain tumor.[5]
Although CMs are clinically not as aggressive as skin 
melanomas, they present substantial risk of developing 
metastases.[3] The biological malignancy of CM 
depends on its morphological, clinical and histological 
type, mitotic activity, cytomorphometric parameters, 
tumor size, tumor location and patient age.[11] Among 
these factors, tumor size is the main indicator for the 
possibility of metastatic disease and, therefore, an 
indicator of survival, as suggested by the Collaborative 
Ocular Melanoma Study (COMS).[2]
In an elegant experimental study, Schackert et al. 
suggested that different human melanoma cells injected 
into the internal carotid artery of nude mice produced 
different patterns of brain metastases.[14] They appeared 
to depend on the source of the original patient’s 
metastases from which the cell lines were derived. Thus, 
only cells originating from brain metastases produced 
parenchymal lesions, while non-brain cells (lymph nodes, 
subcutaneous tissue) produced changes preferentially in 
the meninges, choroid plexus and ventricles.[14]
From the standpoint of molecular biology, it is believed 
that the brain metastatic cells have properties that favor 
the passage through the blood brain barrier. There may 
be a specific interaction with the microenvironment 
of the brain, especially in terms of specific binding to 
endothelial cells and local growth factors receptors.[12] 
Recently, researchers have focused on the expression of 
p75 NGF receptor (NGF-R), which correlates with brain 
metastases and survival of brain-metastatic cell lines of 
epithelioid melanomas, such as CM.[19]
Diagnosing CM can be problematic because the 
symptoms vary greatly, and in some cases, it may be 
easily confused with other common ocular conditions.[4] 
The differential diagnosis includes meningiomas, 
schwannomas, epidermoid cysts, or metastases.[1] The 
treatments include chemotherapy, brachytherapy, 
thermotherapy, and transpupillary enucleation.[9] The 
latter is historically the mainstay of treatment for CM.[3] 
COMS data published in 1998 showed no benefit on 
survival of patients with tumors of large size treated with 
radiotherapy before enucleation.[2] This may be because 
melanoma is resistant to radiotherapy or chemotherapy.[16] 
Thus, some authors have reinforced the need for long 
follow-up of patients treated for CM in order to early 
detect possible late metastases.[1,11]
Metastatic melanoma to the brain is characteristically 
multi-focal and can be hemorrhagic.[7] The treatment for 
solitary lesions is the combination of surgical excision 
and radiotherapy.[8] Multiple lesions can be treated with 
radiation and chemotherapy only.[13] The patient had 
a good outcome (survival of 2 years) with resection, 
radiation therapy, and chemotherapy. This case report 
along with the only two other similar articles found in 
the literature[1,16] show the importance of close, lifelong 
follow-up for all patients treated for CM.
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